Being a synthetic chemist, I have developed a cetain amount of superstition and am always concerned about angering the ‘gods’ of sucess. One thing that I have learned is that nothing puts a jinx on a program more than winning an award. And so it would appear with Pfizer’s Zyvox (linezolid), originally developed by Upjohn prior to the subsequent mergers with Pharmacia and Pfizer.
It seems that in a recent phase III trial where it was tested for its ability to prevent catheter-related infections it actually increased the risk of death and as such the trial has been halted.
The funny thing is, that the team which discovered Zyvox was recently honored by the ACS for this achievement while at the same time the Pharmaceutical Researchers and Manufacturers of America PhRMA) handed out a Clinical Trial Exceptional Servic Award to two researchers involved in the clinical development of the compound….coincidence???